Chimeric Antigen Receptor News and Research

RSS

Study shows new potential target for CAR T cells to inhibit solid tumors

CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.

10 May 2022

A new rule book for the design of therapeutic cells with improved specificity and safety

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.

18 Apr 2022

CDH17CAR T cells can eliminate solid tumors without damaging healthy tissues

Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet.

25 Mar 2022

Leukemia-on-a-chip; The Future of Preventing Therapy Resistance?

We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.

From Society for Laboratory Automation and Screening (SLAS) 27 Jan 2022

CAR T cells produced in vivo using modified mRNA treat cardiac injury

A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.

10 Jan 2022

In vivo generation of engineered CAR T cells to treat heart injury

A novel immunotherapy strategy using in vivo generation of transient engineered chimeric antigen receptor (CAR) T cells, through the delivery of modified mRNA, can reduce fibrosis and restore cardiac function in a mouse model of heart failure, researchers report.

7 Jan 2022

Researchers develop new CAR T cells that act as a "micropharmacy"

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers.

3 Jan 2022

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

13 Dec 2021

Next-generation sequencing for minimal residual disease proven more sensitive than flow cytometry

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

2 Dec 2021

Researchers test a neoantigen-specific transgenic immune cell therapy for malignant gliomas

Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

16 Nov 2021

New gel enhances immunotherapy's effectiveness in glioblastoma

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues.

7 Oct 2021

Clinical efficacy of CAR-T cells depends on chemical modifications, says study

One in five cancers affects lymph nodes and blood cells resulting in lymphomas and leukemias, respectively.

7 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Researchers engineer CAR T cells to enhance their function

Chimeric antigen receptor (CAR) T cell therapy employs engineered T cells to treat certain kinds of cancers.

7 Sep 2021

Researchers develop heat-controllable CAR T cells to kill tumors and prevent relapse

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

19 Aug 2021

Mayo Clinic researchers examine potential new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

28 Jun 2021

Small molecular changes can have dramatic impact on the CAR T cell function

When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.

23 Apr 2021

Researchers use mathematical modeling to explain CAR T-cell therapy dynamics

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

26 Mar 2021

Study advances CAR T cell therapy targeted at cancer

Cancer immunotherapy involves the activation of cells in the patient’s own immune system to fight tumor cells.

19 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021